Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21159780 | 1.00 | CFD (0.65) | CFD | |
| SCHEMBL18578372 | 1.00 | CFD (0.65) | CFD | |
| SCHEMBL18578486 | 1.00 | CFD (0.65) | CFD | |
| SCHEMBL29545061 | 1.00 | CFD (0.65) | CFD | |
| SCHEMBL18578476 | 1.00 | CFD (0.65) | CFD | |
| SCHEMBL21159550 | 1.00 | CFD (0.65) | CFD | |
| SCHEMBL20992551 | 1.00 | CFD (0.65) | CFD | |
| SCHEMBL20992561 | 1.00 | CFD (0.65) | CFD | |
| SCHEMBL18611647 | 0.95 | CFD (0.57) | CFD | |
| SCHEMBL18611097 | 0.93 | CFD (0.61) | CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4053117-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114044800-A | Aryl, heteroaryl and heterocyclic compounds for the treatment of medical disorders | 艾其林医药公司 | 2022-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | CFD 1/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CFD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.